...
jagx-img

Jaguar Animal Health Inc, Common Stock

JAGX

NAQ

$0.8731

+$0.01

(1.16%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$10.15M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0.0426
Volume info-icon
This is the total number of shares traded during the most recent trading day.
337.29K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.88
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.84 L
$21.6 H
$0.8731

About Jaguar Animal Health Inc, Common Stock

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameJAGXSectorS&P500
1-Week Return-10.45%-3.35%-2.97%
1-Month Return-9.99%-3.49%-0.66%
3-Month Return-21.34%-12.6%2.71%
6-Month Return-78.06%-6.91%7.21%
1-Year Return-91.02%1.19%23.04%
3-Year Return-99.98%-0.21%28.43%
5-Year Return-99.99%33.09%82.88%
10-Year Return-100%93.55%184.63%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue5.78M9.38M4.33M11.96M9.76M[{"date":"2019-12-31","value":48.3,"profit":true},{"date":"2020-12-31","value":78.5,"profit":true},{"date":"2021-12-31","value":36.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":81.64,"profit":true}]
Cost of Revenue3.82M3.28M2.33M2.02M2.04M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.96,"profit":true},{"date":"2021-12-31","value":61.14,"profit":true},{"date":"2022-12-31","value":52.91,"profit":true},{"date":"2023-12-31","value":53.38,"profit":true}]
Gross Profit1.96M6.11M2.00M9.94M7.72M[{"date":"2019-12-31","value":19.72,"profit":true},{"date":"2020-12-31","value":61.44,"profit":true},{"date":"2021-12-31","value":20.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":77.73,"profit":true}]
Gross Margin33.93%65.05%46.18%83.11%79.13%[{"date":"2019-12-31","value":40.82,"profit":true},{"date":"2020-12-31","value":78.27,"profit":true},{"date":"2021-12-31","value":55.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.21,"profit":true}]
Operating Expenses26.91M27.41M41.08M44.35M42.02M[{"date":"2019-12-31","value":60.67,"profit":true},{"date":"2020-12-31","value":61.8,"profit":true},{"date":"2021-12-31","value":92.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.73,"profit":true}]
Operating Income(24.95M)(21.30M)(39.07M)(34.41M)(34.29M)[{"date":"2019-12-31","value":-2494811100,"profit":false},{"date":"2020-12-31","value":-2130400000,"profit":false},{"date":"2021-12-31","value":-3907400000,"profit":false},{"date":"2022-12-31","value":-3441500000,"profit":false},{"date":"2023-12-31","value":-3429100000,"profit":false}]
Total Non-Operating Income/Expense(19.31M)(15.30M)(21.95M)(26.70M)(16.38M)[{"date":"2019-12-31","value":-1931197300,"profit":false},{"date":"2020-12-31","value":-1529700000,"profit":false},{"date":"2021-12-31","value":-2194700000,"profit":false},{"date":"2022-12-31","value":-2670300000,"profit":false},{"date":"2023-12-31","value":-1637800000,"profit":false}]
Pre-Tax Income(38.53M)(33.81M)(52.60M)(48.40M)(41.90M)[{"date":"2019-12-31","value":-3852943600,"profit":false},{"date":"2020-12-31","value":-3380900000,"profit":false},{"date":"2021-12-31","value":-5260000000,"profit":false},{"date":"2022-12-31","value":-4839500000,"profit":false},{"date":"2023-12-31","value":-4190100000,"profit":false}]
Income Taxes10.00K2.98M7.65M(941.00K)(601.00K)[{"date":"2019-12-31","value":0.13,"profit":true},{"date":"2020-12-31","value":38.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-12.3,"profit":false},{"date":"2023-12-31","value":-7.86,"profit":false}]
Income After Taxes(38.54M)(36.79M)(60.25M)(47.45M)(41.30M)[{"date":"2019-12-31","value":-3853943600,"profit":false},{"date":"2020-12-31","value":-3679100000,"profit":false},{"date":"2021-12-31","value":-6025100000,"profit":false},{"date":"2022-12-31","value":-4745400000,"profit":false},{"date":"2023-12-31","value":-4130000000,"profit":false}]
Income From Continuous Operations(38.54M)(33.81M)(52.60M)(48.40M)(40.82M)[{"date":"2019-12-31","value":-3853943600,"profit":false},{"date":"2020-12-31","value":-3380900000,"profit":false},{"date":"2021-12-31","value":-5260000000,"profit":false},{"date":"2022-12-31","value":-4839500000,"profit":false},{"date":"2023-12-31","value":-4082400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(38.54M)(36.79M)(60.25M)(47.45M)(41.30M)[{"date":"2019-12-31","value":-3853943600,"profit":false},{"date":"2020-12-31","value":-3679100000,"profit":false},{"date":"2021-12-31","value":-6025100000,"profit":false},{"date":"2022-12-31","value":-4745400000,"profit":false},{"date":"2023-12-31","value":-4130000000,"profit":false}]
EPS (Diluted)-(5.55K)(88.50)(51.43)(36.63)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-555300,"profit":false},{"date":"2021-12-31","value":-8850,"profit":false},{"date":"2022-12-31","value":-5142.97,"profit":false},{"date":"2023-12-31","value":-3662.81,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

JAGX
Cash Ratio 0.67
Current Ratio 1.84
Quick Ratio 1.36

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

JAGX
ROA (LTM) -34.53%
ROE (LTM) -290.94%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

JAGX
Debt Ratio Lower is generally better. Negative is bad. 0.78
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.23

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

JAGX
Trailing PE 0.04
Forward PE NM
P/S (TTM) 1.00
P/B 0.76
Price/FCF NM
EV/R 2.99
EV/Ebitda NM
PEG NM

FAQs

What is Jaguar Animal Health Inc share price today?

Jaguar Animal Health Inc (JAGX) share price today is $0.8731

Can Indians buy Jaguar Animal Health Inc shares?

Yes, Indians can buy shares of Jaguar Animal Health Inc (JAGX) on Vested. To buy Jaguar Animal Health Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in JAGX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Jaguar Animal Health Inc be purchased?

Yes, you can purchase fractional shares of Jaguar Animal Health Inc (JAGX) via the Vested app. You can start investing in Jaguar Animal Health Inc (JAGX) with a minimum investment of $1.

How to invest in Jaguar Animal Health Inc shares from India?

You can invest in shares of Jaguar Animal Health Inc (JAGX) via Vested in three simple steps:

  • Click on Sign Up or Invest in JAGX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Jaguar Animal Health Inc shares
What is Jaguar Animal Health Inc 52-week high and low stock price?

The 52-week high price of Jaguar Animal Health Inc (JAGX) is $21.6. The 52-week low price of Jaguar Animal Health Inc (JAGX) is $0.84.

What is Jaguar Animal Health Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Jaguar Animal Health Inc (JAGX) is 0.0426

What is Jaguar Animal Health Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Jaguar Animal Health Inc (JAGX) is 0.76

What is Jaguar Animal Health Inc dividend yield?

The dividend yield of Jaguar Animal Health Inc (JAGX) is 0.00%

What is the Market Cap of Jaguar Animal Health Inc?

The market capitalization of Jaguar Animal Health Inc (JAGX) is $10.15M

What is Jaguar Animal Health Inc’s stock symbol?

The stock symbol (or ticker) of Jaguar Animal Health Inc is JAGX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top